Amphivena Therapeutics, Inc logo

Amphivena Therapeutics, Inc

Amphivena Therapeutics (subsidiary of Affimed AG), is developing a first-in-class bi-functional antibody therapy to address blood cancer indications with high unmet medical needs.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://amphivena.com
Founded2012
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
45 Juniper Street, CA 94103
South San Francisco
United States
Email
Contact Number
+1 415-994-6455

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/amphivena-therapeutics-inc-” connections=”true” suffix=””]

In 2013, Amphivena has entered into an agreement with Janssen Biotech, that grants Janssen the exclusive right, to acquire Amphivena going forward following IND approvals. As per terms, Janssen will provide Amphivena with an initial upfront payment plus additional contingent payments based on reaching predetermined milestones in return for its rights under the agreement.

Affimed AG has entered into a license and development agreement with Amphivena to support the discovery and pre-clinical development of the novel TandAb based therapy.

In July 2013, Amphivena completed a $14 Mn Series A equity financing led by MPM Capital, with participation from Aeris Capital and Affimed AG.